Section 1: Introduction — The Prescription That Stops Working

A 45-year-old woman in Kingston presents with dysuria and frequency. The diagnosis is uncomplicated urinary tract infection. She is prescribed ciprofloxacin 500 mg twice daily for seven days.

Three things are wrong with this prescription.

First, ciprofloxacin is a fluoroquinolone — a broad-spectrum antibiotic reserved for complicated infections or infections caused by resistant organisms. Using it for an uncomplicated UTI is unnecessary escalation. Nitrofurantoin or trimethoprim would have been sufficient.

Second, seven days is too long. Current guidelines recommend three days for uncomplicated lower UTI in women. The additional four days provide no clinical benefit and increase the risk of adverse effects, gut microbiome disruption, and resistance selection.

Third, ciprofloxacin carries specific risks that are disproportionate to the condition being treated: tendon rupture, QT prolongation, peripheral neuropathy, C. difficile infection, and — in patients with renal impairment (Report 2) — CNS toxicity. These risks are acceptable when treating a serious infection. They are not acceptable for a condition that resolves with a narrower, safer agent.

This prescription is written every day in Caribbean clinical practice. It is not the result of ignorance — it is the result of habit, formulary convenience, and the absence of local antibiotic stewardship guidance that reflects Caribbean resistance patterns and formulary realities.

1.1 Why this report matters for the Caribbean

Antimicrobial resistance (AMR) is a global crisis, but it does not affect all regions equally. The Caribbean faces specific challenges:

Antibiotic availability without prescription. In several Caribbean territories, antibiotics can be purchased over the counter or with minimal prescriber oversight. Patients self-treat with amoxicillin, metronidazole, or ciprofloxacin for conditions that may not require antibiotics at all.

Limited microbiological capacity. Culture and sensitivity testing is not routinely available in many Caribbean primary care settings. Clinicians prescribe empirically — based on best guess rather than confirmed susceptibility. When the empirical choice is too broad, resistance is selected unnecessarily.

Formulary constraints driving inappropriate choices. If the formulary contains ciprofloxacin but not nitrofurantoin, the clinician uses ciprofloxacin. If amoxicillin-clavulanate is available but amoxicillin alone is not, the broader-spectrum combination is used by default. Formulary composition shapes prescribing patterns more than guidelines do.

Incomplete courses and inappropriate durations. Patients stop antibiotics when they feel better, or continue them longer than necessary because the prescribed duration was wrong. Both behaviours promote resistance.

1.2 What this report covers

This report profiles fifteen common antibiotic prescribing errors in Caribbean practice — not rare or exotic mistakes, but the routine prescribing decisions that are made incorrectly every day. Each profile covers what the error is, why it happens, what the correct approach is, and the drug interactions and safety flags that ElesRx monitors.

The report also provides a quick-reference antibiotic selection table for the five most common outpatient infections seen in Caribbean primary care.

Section 2: Fifteen Antibiotic Prescribing Errors

Error 1: Ciprofloxacin for uncomplicated UTI

The error: Using a fluoroquinolone as first-line therapy for uncomplicated lower urinary tract infection in women.

Why it happens: Ciprofloxacin is available on most Caribbean formularies, is familiar, and has broad-spectrum coverage. It feels like a safe empirical choice.

The correct approach: Nitrofurantoin 100 mg twice daily for 5 days, or trimethoprim 200 mg twice daily for 3 days, are the recommended first-line agents for uncomplicated lower UTI. Ciprofloxacin should be reserved for complicated UTI, pyelonephritis, or documented resistant organisms.

ElesRx flags: Ciprofloxacin requires renal dose adjustment at CrCl below 30 (Report 2). It also prolongs the QT interval and interacts with other QT-prolonging drugs (Report 1, Section 3, Theme 3). ElesRx flags both automatically.

Error 2: Amoxicillin-clavulanate when amoxicillin alone is sufficient

The error: Prescribing co-amoxiclav (amoxicillin + clavulanic acid) for infections where amoxicillin alone would be adequate — simple pharyngitis, uncomplicated otitis media, dental infections.

Why it happens: Co-amoxiclav is perceived as "stronger." In some Caribbean pharmacies, it is more readily available than plain amoxicillin. Clinicians reach for the combination as a default.

The correct approach: Amoxicillin alone is first-line for Group A streptococcal pharyngitis, uncomplicated otitis media, and most dental infections. The clavulanic acid component adds beta-lactamase coverage that is unnecessary for these organisms and increases GI adverse effects (diarrhoea in up to 25% of patients).

Error 3: Azithromycin for everything

The error: Using azithromycin as a default empirical antibiotic for upper and lower respiratory tract infections, regardless of the likely organism.

Why it happens: Azithromycin has convenient dosing (3-day or 5-day course), good patient compliance, and broad coverage including atypical organisms. It has become the default "just in case" antibiotic in Caribbean practice.

The correct approach: Most upper respiratory tract infections are viral and require no antibiotic. For community-acquired pneumonia in otherwise healthy adults, amoxicillin is first-line. Azithromycin is appropriate for atypical pneumonia, Legionella, or in penicillin-allergic patients — not as a blanket first choice.

ElesRx flags: Azithromycin prolongs the QT interval. In combination with other QT-prolonging drugs (haloperidol, amiodarone, domperidone, ondansetron at high doses), the risk of torsades de pointes is increased. ElesRx flags these combinations automatically.

Error 4: Metronidazole "just in case"

The error: Adding metronidazole to an antibiotic regimen "to cover anaerobes" without a clear indication for anaerobic coverage.

Why it happens: Metronidazole is inexpensive, widely available, and has become a reflex addition to empirical regimens for abdominal complaints, gynaecological infections, and even some respiratory infections where anaerobic coverage is not indicated.

The correct approach: Metronidazole is indicated for confirmed or strongly suspected anaerobic infections (intra-abdominal sepsis, pelvic inflammatory disease, C. difficile colitis, amoebic dysentery, bacterial vaginosis). It should not be added empirically to regimens that already provide adequate coverage. Long-term use causes peripheral neuropathy (Report 4, Drug 13).

Error 5: Seven-day courses where three days is sufficient

The error: Prescribing seven-day antibiotic courses for conditions where shorter courses are equally effective.

Why it happens: The "seven-day course" is deeply embedded in prescribing culture. Clinicians default to it regardless of the infection being treated.

The correct approach:

Shorter courses reduce adverse effects, costs, microbiome disruption, and resistance selection without compromising cure rates.

Error 6: Antibiotics for viral upper respiratory tract infections

The error: Prescribing antibiotics for the common cold, viral pharyngitis, or acute bronchitis in otherwise healthy adults.

Why it happens: Patient expectation. In Caribbean practice, patients often attend the clinic specifically to "get the antibiotic" and may express dissatisfaction if they leave without a prescription. Clinicians prescribe to maintain the therapeutic relationship, to manage time pressure, or because they are uncertain whether the infection is viral or bacterial.

The correct approach: Explain that most upper respiratory infections are viral and resolve without antibiotics. Symptomatic treatment (paracetamol, hydration, rest) is appropriate. If the clinician suspects bacterial superinfection (persistent fever beyond 10 days, purulent nasal discharge, worsening after initial improvement), antibiotics are then indicated.

Error 7: Not adjusting antibiotic dose for renal function

The error: Prescribing renally-cleared antibiotics at standard doses in patients with chronic kidney disease.

Why it happens: Renal function is not checked before prescribing. Or it is checked but the dose adjustment is not made. This is the same problem described in Report 2, applied specifically to antibiotics.

Key antibiotics requiring renal adjustment:

Error 8: Nitrofurantoin in renal impairment

The error: Prescribing nitrofurantoin for UTI in a patient with CrCl below 30.

Why it happens: Nitrofurantoin is the recommended first-line for uncomplicated UTI. Clinicians reach for it without checking renal function.

The correct approach: Nitrofurantoin requires adequate renal function to concentrate in the urine. At CrCl below 30, it fails to reach therapeutic urinary concentrations (making it ineffective) and systemic accumulation increases the risk of pulmonary fibrosis and peripheral neuropathy. Use trimethoprim, fosfomycin (where available), or a cephalosporin instead.

Error 9: Prophylactic antibiotics continued indefinitely

The error: Continuing antibiotic prophylaxis (for recurrent UTIs, surgical wound prevention, or rheumatic fever) beyond the recommended duration without review.

Why it happens: The prophylaxis is started with a clear indication and duration. But nobody sets a stop date, nobody reviews it, and the antibiotic continues for months or years. This is the same deprescribing failure described in Report 4, Drug 12.

The correct approach: UTI prophylaxis: typically 6–12 months, then reassess. Surgical prophylaxis: 24 hours post-procedure maximum. Rheumatic fever prophylaxis: duration depends on severity, valve involvement, and age — refer to current guidelines (WHO recommends at least 10 years or until age 40, whichever is longer, for rheumatic heart disease with carditis).

Error 10: Ignoring the drug interactions

The error: Prescribing an antibiotic without checking for interactions with the patient's existing medications.

Why it happens: Antibiotics are perceived as short-term additions that are unlikely to cause interactions. This perception is wrong.

Key antibiotic interactions flagged by ElesRx:

These interactions are documented in Report 1 and flagged automatically by ElesRx. The point here is that they are most commonly missed when an antibiotic is added to an existing medication list during an acute infection — precisely the clinical scenario where time pressure is highest and interaction checking is most likely to be skipped.

Error 11: Topical antibiotics for conditions requiring systemic treatment

The error: Using topical antibiotics (mupirocin, fusidic acid) for skin infections that require systemic therapy — cellulitis, infected wounds with surrounding erythema, folliculitis with systemic features.

Why it happens: Topical treatment feels less invasive and avoids the perceived complexity of systemic prescribing. In some cases, the patient requests a cream rather than tablets.

The correct approach: Topical antibiotics are appropriate for minor, localised skin infections (impetigo, small infected abrasions). When infection extends beyond the immediate wound — erythema spreading beyond 2 cm, lymphangitis, fever, or systemic symptoms — systemic antibiotics are required. Flucloxacillin is first-line for non-purulent cellulitis; incision and drainage plus doxycycline or trimethoprim-sulfamethoxazole for purulent infections.

Error 12: Not completing the switch from IV to oral

The error: Continuing intravenous antibiotics in hospital beyond the point where the patient could safely switch to oral therapy.

Why it happens: The switch from IV to oral antibiotics requires a clinical decision — assessment of clinical response, oral tolerance, and identification of an appropriate oral agent. In busy Caribbean wards, this decision may be deferred from day to day, prolonging hospital stay, increasing cost, and increasing the risk of line-related complications.

The correct approach: Assess for IV-to-oral switch daily. Criteria: clinical improvement (defervescence, improving inflammatory markers), functioning GI tract, and an appropriate oral option available. Most patients with community-acquired pneumonia, UTI, and skin/soft tissue infections can switch at 48–72 hours.

Error 13: Double anaerobic coverage

The error: Prescribing metronidazole alongside amoxicillin-clavulanate or piperacillin-tazobactam — regimens that already contain adequate anaerobic coverage.

Why it happens: Metronidazole is added reflexively "for anaerobes" without recognising that the primary antibiotic already covers anaerobic organisms. Clavulanic acid and tazobactam both provide anaerobic coverage through beta-lactamase inhibition.

The correct approach: Check whether the existing regimen already covers anaerobes before adding metronidazole. If the primary agent includes a beta-lactamase inhibitor (co-amoxiclav, piperacillin-tazobactam, ampicillin-sulbactam), additional metronidazole is redundant and adds adverse effect risk without clinical benefit.

Error 14: Gentamicin without monitoring

The error: Prescribing gentamicin without monitoring serum levels and renal function.

Why it happens: Gentamicin monitoring requires timed blood sampling and laboratory support that may not be readily available in all Caribbean hospitals. The drug is prescribed because it is effective and available; monitoring is deferred or omitted.

The correct approach: Gentamicin is ototoxic and nephrotoxic. Therapeutic drug monitoring is mandatory — not optional. If monitoring capability is not available, an alternative antibiotic should be used. For empirical Gram-negative coverage without monitoring capability, a third-generation cephalosporin (ceftriaxone) is a safer choice.

Error 15: Not considering C. difficile risk

The error: Prescribing broad-spectrum antibiotics — particularly fluoroquinolones, clindamycin, and broad-spectrum cephalosporins — without considering the risk of Clostridioides difficile infection.

Why it happens: C. difficile is perceived as a hospital-acquired infection relevant to intensive care. In reality, community-acquired C. difficile is increasingly recognised, and any antibiotic exposure increases risk. Older adults and patients on PPIs (Report 4) are at highest risk.

The correct approach: Use the narrowest-spectrum antibiotic effective for the infection. Avoid fluoroquinolones, clindamycin, and broad-spectrum cephalosporins where narrower agents are available. In patients who develop diarrhoea during or after antibiotic therapy, consider C. difficile and test before prescribing anti-diarrhoeal agents (which can worsen C. difficile colitis).

Section 3: Quick-Reference Antibiotic Selection

Five common outpatient infections. Evidence-based first-line choices.

One principle: Start narrow. Escalate only if culture results or clinical response require it. Broad-spectrum empirical therapy is appropriate for severe or complicated infections — not for the routine outpatient conditions that make up the majority of Caribbean antibiotic prescriptions.

Section 4: About ElesRx

Every antibiotic interaction listed in this report is flagged automatically by ElesRx. When a clinician adds an antibiotic to a patient's medication list, the system checks for drug-drug interactions (ciprofloxacin + warfarin, azithromycin + QT-prolonging drugs, rifampicin + oral contraceptives), renal dose adjustments (ciprofloxacin, nitrofurantoin, co-trimoxazole, gentamicin), and therapeutic duplications (double anaerobic coverage).

The antibiotic selection table in Section 3 is a starting point. ElesRx provides patient-specific analysis that accounts for the full medication list, renal function, age, and clinical context.

elesrx.com — free tier available. Full access $9.99/month.

ElesRx is a product of PIPPS Smart Apps, a division of J.C. Epiphany Limited (Jamaica, est. 1998).

Section 5: Methodology and References

5.1 Data sources

Antibiotic prescribing recommendations are drawn from published international guidelines (NICE, IDSA, BSAC, WHO AWaRe classification), the ElesRx clinical database, and the Caribbean-specific sources cited below. Drug interaction data references the ElesRx interaction database (Report 1). Renal adjustment data references Report 2.

5.2 Limitations

Antibiotic resistance patterns vary by territory, by hospital, and over time. The empirical recommendations in this report reflect general principles and published guidelines — they are not a substitute for local antibiograms where available. Clinicians should consult local resistance data when making empirical prescribing decisions.

This report focuses on outpatient and general ward prescribing. ICU-level antimicrobial stewardship and management of multi-drug resistant organisms are beyond its scope.

5.3 Author and conflict of interest disclosure

This report was authored by Juliet Duncan, BPharm, founder of J.C. Epiphany Limited and developer of ElesRx. The author has a commercial interest in ElesRx. This report is published freely as a contribution to Caribbean clinical education. No external funding was received.

5.4 Citation

Duncan J. The Caribbean Antibiotic Report: What We're Prescribing Wrong. ElesRx Clinical Reports, Report 6. Published 2026 at elesrx.com/reports/caribbean-antibiotic-report/. J.C. Epiphany Limited, Jamaica.

References

1. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clin Infect Dis. 2011;52(5):e103–e120. doi:10.1093/cid/ciq257

2. Lim WS, et al. British Thoracic Society community acquired pneumonia in adults guideline. Thorax. 2009;64(Suppl III):iii1–iii55. doi:10.1136/thx.2009.121434

3. WHO AWaRe (Access, Watch, Reserve) antibiotic classification. World Health Organization. 2021.

4. Pan American Health Organization. Antimicrobial resistance in the Americas — regional report. PAHO/WHO. 2023.

5. Spellberg B, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community. Clin Infect Dis. 2008;46(2):155–164. doi:10.1086/524891

6. Uranga A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med. 2016;176(9):1257–1265. doi:10.1001/jamainternmed.2016.3633